Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) have been assigned an average rating of “Moderate Buy” from the eight analysts that are presently covering the company, Marketbeat reports. Five analysts have rated the stock with a hold recommendation and three have issued a strong buy recommendation on the company.

Several brokerages have weighed in on ZLDPF. BNP Paribas Exane cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Finally, William Blair reiterated a “market perform” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th.

Zealand Pharma A/S Price Performance

Shares of OTCMKTS:ZLDPF opened at $47.47 on Monday. The company has a current ratio of 23.57, a quick ratio of 23.57 and a debt-to-equity ratio of 0.02. The stock’s fifty day simple moving average is $48.30 and its two-hundred day simple moving average is $64.20. Zealand Pharma A/S has a 1-year low of $35.93 and a 1-year high of $83.12. The stock has a market cap of $3.40 billion, a PE ratio of 3.47 and a beta of 0.88.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its quarterly earnings data on Thursday, February 19th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($1.34) by $0.53. Zealand Pharma A/S had a return on equity of 48.10% and a net margin of 70.06%.The business had revenue of $10.79 million for the quarter, compared to analysts’ expectations of $19.69 million. As a group, analysts forecast that Zealand Pharma A/S will post 2.51 EPS for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.